Translational Basic and Clinical Research Training in Rheumatology

由纽约大学牵头的风湿病基础和临床研究转化型培训 风湿科主任Jill Buyon博士将在MPI安排下担任第二周期的联合导演。 除了Buyon博士在SLE和自身免疫方面丰富的翻译经验外，Jose Scher博士还提供了 在炎症性关节炎方面的互补专业知识，包括牛皮癣和类风湿性关节炎。我们的使命 仍然明确：支持学员度过更长的发展期；利用新出现的研究 吸引和激励医生的机会；并将临床背景带到博士预科医生的长凳上。 因此，我们的计划扩展了传统的ACGME培训，并再次建议支持为期2年的3 奖学金毕业生，外加1名博士前医学博士/博士候选人，以建立风湿病的早期渠道。在我们的 前4年：a)3名风湿学毕业生完成培训(2名晋升纽约大学外部教员职位 多年期赠款和出版物，1根据成就在行业中发挥领导作用；b) 2名博士前医学博士/博士实习生成功地通过出版物为一篇博士论文辩护；c)3名研究员和1名博士/博士 候选人(URM)继续接受培训；d)纽约大学2名初级教员晋升为初级导师，获得新的R01奖 E)招聘了I型干扰素专家Timothy Niewold博士；f)增加了新的NIH研究计划， 包括临床前和临床狼疮的P50，以及作为AMP的一部分的SLE的肾脏和皮肤转录 针对新冠肺炎和大流行期间产生的风湿病的临床/基础研究方案 让实习生和教职员工担负起前所未有的耐心责任。处于...的核心 目前的提议是沿着两个方法上不同的研究轨道进行跨学科培训，每个研究轨道都带有 前缀“翻译”--基本的或临床的--以强调所有医疗保健研究人员的共同目的。一大早 科学家之路再次提供给通过我校医学博士和研究生招聘的医学博士研究生 计划，包括免疫学/炎症计划和新成立的翻译研究 免疫中心(TIC)。培训路径以核心疾病群为基础，反映教师的专业知识和 国家认可的领导力：1)狼疮和系统性自身免疫性疾病；2)炎症性和 自身免疫性关节炎；3)退行性和代谢性骨病。每一个都包含公共的和 定制化教学；与小学、助理和 整合科学和医学的方法论导师；每个人都有一个精心挑选的咨询指导委员会 实习生；并计划支持T32后的教职员工晋升。尽管如此，计划的成功还是要评估的 执行委员会会议和年度展示撤退。强有力的机构承诺支持 基础设施和额外资金。两次更新的临床/翻译科学研究所提供广泛的 资源。这一T32计划代表了我们能力建设和科学奉献的持续轨迹， 肯定并扩大对风湿病高级培训的承诺。

The Translational Basic and Clinical Research Training in Rheumatology, led in its first cycle by NYU Rheumatology Division Director Dr. Jill Buyon, will in its second cycle be co-directed under an mPI arrangement. Adding to Dr. Buyon’s extensive translational experience in SLE and autoimmunity, Dr. Jose Scher provides complementary expertise in inflammatory arthridities, including psoriatic and rheumatoid arthritis. Our mission remains clear: to support trainees through an extended period of development; to leverage emerging research opportunities to engage and excite physicians; and to bring clinical context to the pre-doctoral bench. Accordingly, our program extends traditional ACGME training and again proposes support for 2-yr training of 3 fellowship graduates, plus 1 predoctoral MD/PhD candidate to establish an early pipeline to rheumatology. In our first 4 years: a) 3 rheumatology graduates completed training (2 advancing to NYU faculty positions with external multi-year grants and publications, and 1 garnering a leadership role in industry based on accomplishments; b) 2 pre-doctoral MD/PhD trainees successfully defended a PhD thesis with publications; c) 3 fellows and 1 MD/PhD candidate (URM) remain in training; d) 2 NYU junior faculty advanced as Primary Mentors with new R01 awards e) Dr. Timothy Niewold, expertise in type I Interferon, was recruited; f) new NIH research programs were added, including a P50 in preclinical and clinical lupus, and renal and skin transcriptomics in SLE as part of AMP; g) clinical/basic research programs addressing COVID-19 and rheumatic diseases spawned during the pandemic engaged the pivot of trainees and faculty as they assumed unprecedented patient responsibilities. At the core of the present proposal is interdisciplinary training along 2 methodologically distinct research tracks, each bearing the prefix “translational” –basic or clinical – to emphasize the common purpose of all healthcare investigators. An Early Scientist Pathway is again offered to MD/PhD candidates recruited through our school’s MD/PhD and graduate programs, including the Immunology/Inflammation program and the newly established Translational Research Immunology Center (TrIC). Training tracks are grounded in core disease clusters reflecting faculty expertise and nationally recognized leadership: 1) lupus and diseases of systemic autoimmunity; 2) inflammatory and autoimmune arthritis; and 3) degenerative and metabolic bone disease. Each incorporates common and customized didactics; individualized research training experiences with teams of Primary, Associate, and Methodological Mentors to integrate science and medicine; a hand-picked Advisory Mentoring Committee for each trainee; and planning to support post-T32 faculty advancement. Programmatic success is evaluated though Executive Committee meetings and an Annual Showcase Retreat. Strong institutional commitment supports infrastructure and additional funding. The twice-renewed Clinical/Translational Science Institute provides extensive resources. This T32 program represents the ongoing trajectory of our capacity-building and scientific dedication, affirming and expanding commitment to advanced training in the rheumatic diseases.